EBITDA: Income before interest, taxes, depreciation and amortization.
Revelation Biosciences, Inc. (REVB) had EBITDA of $-9.04M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-14.87M |
|
-- |
|
-- |
|
$9.07M |
|
$-9.07M |
|
$0.16M |
|
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-9.07M |
|
|
EBITDA |
$-9.04M |
0.62M |
|
0.62M |
|
$-23.95 |
|
$-23.95 |
|
| Balance Sheet Financials | |
$10.81M |
|
$0.02M |
|
$0.77M |
|
$11.58M |
|
$2.00M |
|
-- |
|
$0.72M |
|
$2.72M |
|
$8.86M |
|
$8.86M |
|
$8.86M |
|
1.58M |
|
| Cash Flow Statement Financials | |
$-8.27M |
|
-- |
|
$12.47M |
|
$6.50M |
|
$10.70M |
|
$4.20M |
|
$0.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-100.59% |
|
-100.59% |
|
-76.96% |
|
-100.59% |
|
$5.59 |
|
$-13.32 |
|
$-13.32 |
|